trending Market Intelligence /marketintelligence/en/news-insights/trending/ml1s94ppHhqo1YMZAFm1rQ2 content esgSubNav
In This List

Vical, Brickell Biotech complete merger, begin trading on Nasdaq

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Vical, Brickell Biotech complete merger, begin trading on Nasdaq

San Diego-based Vical Inc. and Boulder, Colo.-based Brickell Biotech Inc. completed their previously approved merger, with the combined company operating under the name of Brickell Biotech Inc.

Following the completion of the merger, the combined company has about 7.8 million outstanding common shares. Brickell's stockholders received about 56% of outstanding shares while Vical's stockholders held onto about 44%.

Last week, Vical's board approved a 1-for-7 reverse split. The combined company, Brickell Biotech Inc., will begin trading on the post-split basis on the Nasdaq Capital Market today under the ticker symbol BBI.